If you are looking for an uncommon opportunity -- a chance to join an organization known for its scientific excellence in the research and development of pharmaceuticals -- it's time to consider Regeneron.
Regeneron is a fully integrated biopharmaceutical company that discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions. Regeneron markets three products in the United States, EYLEA® (aflibercept) Injection, ZALTRAP® (ziv-aflibercept) Injection for Intravenous Infusion, and ARCALYST® (rilonacept) Injection for Subcutaneous Use; ZALTRAP is co-commercialized with Sanofi. Phase 3 studies are in progress with EYLEA in two additional indications and with product candidates sarilumab and REGN727. Regeneron has active research and development programs in many disease areas, including ophthalmology, inflammation, cancer, and hypercholesterolemia.
Summary:
Summary: We are looking for a highly motivated Scientist to join the Proteomics and Biomarkers group within the Therapeutic Proteins team. A Ph.D. level scientist is needed to carry out labeled (SILAC) and non-labeled quantitative proteomic analysis of preclinical samples for biomarker discovery. The candidate must have extensive hands on experience running and maintaining Orbitrap instruments.
Responsibilities include, but are not limited to:
- Develop and optimize subcellular fractionation methods for in-depth proteomics
- Carry out label-free quantitative proteomic analysis of preclinical samples for biomarker discovery
- Supervise research associates in performing routine proteomic workflow such as multiple enzymatic digestion, OFFGel separation of peptides, GELFREE fractionation of proteins, LC-MALDI, and NanoLC-MS/MS
- Maintain the operation of Orbitrap Elite mass spectrometer coupled with EASY-nLC II